Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | UGCG | Q16739 | 2/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21048748 | 1.00 | HSD11B1 (0.50) | HSD11B1CYP2C9EPHX2GBA1UGCG | |
| SCHEMBL16567928 | 1.00 | HSD11B1 (0.50) | HSD11B1CYP2C9EPHX2GBA1UGCG | |
| SCHEMBL21426648 | 0.82 | HSD11B1 (0.37) | HSD11B1CYP2C9GBA1UGCGGBA2 | |
| SCHEMBL8057669 | 0.82 | HSD11B1 (0.38) | HSD11B1CYP2C9EPHX2GBA1UGCG | |
| SCHEMBL22642716 | 0.80 | HSD11B1 (0.39) | HSD11B1CYP2C9 | |
| SCHEMBL2747594 | 0.77 | HSD11B1 (0.46) | HSD11B1CYP2C9EPHX2 | |
| SCHEMBL3318288 | 0.71 | — | — | |
| SCHEMBL13398605 | 0.71 | — | — | |
| SCHEMBL1066102 | 0.69 | — | — | |
| SCHEMBL1924918 | 0.69 | HSD11B1 (0.61) | HSD11B1CYP2C9EPHX2CXCR3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013111158-A2 | PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR | MSN LABORATORIES LIMITED (IN) | 2013-08-01 | — | — | WO | claimed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-06 | — | — | US | disclosed |
| EP-4090664-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | Bristol-Myers Squibb Company (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115244061-A | Reagents and their use for modular enantioselective synthesis of C-P bonds | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20210228565-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-7402712-B2 | Adamantyl vinyl ether compound and production process for the same | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070015793-A1 | Synthesis of nojirimycins | MACROZYME DNM B.V. (NL) | 2007-01-18 | — | — | US | disclosed |
| US-20070015026-A1 | Membrane-electrode assembly for solid polymer electrolyte fuel cell | HONDA MOTOR CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| WO-2005063706-A1 | SYNTHESIS OF NOJIRIMYCINS | MACROZYME DNM B.V. (NL) | 2005-07-14 | — | — | WO | disclosed |
| US-20050004391-A1 | Adamantyl vinyl ether compound and production process for the same | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1486480-A1 | Adamantyl vinyl ether compound and production process for the same | Idemitsu Petrochemical Co., Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-6238842-B1 | SUITABLE FOR USE WITH AN EXPOSURE LIGHT HAVING A WAVELENGTH OF 250 NM OR SHORTER, ESPECIALLY 220 NM OR SHORTER; ACID GENERATING COMPOUND; RESIN HAVING MONOVALENT POLYALICYCLIC GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| US-4739078-A | Use of borohydride-salt lanthanide salt reagents for stereo selective reduction of C-15-keto prostaglandin precursors | THE UPJOHN COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0219580-A1 | Stereo-selective reduction | THE UPJOHN COMPANY (US) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004391-A1 | Adamantyl vinyl ether compound and production process for the same | NOTUM, CYP4A11, CYP4F11 | HSD11B1 74/4885CYP2C9 214/4885EPHX2 533/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | HSD11B1 2238/4885CYP2C9 2179/4885EPHX2 1260/4885 |
| US-20070015793-A1 | Synthesis of nojirimycins | DHPS, NOS1, MRM1 | HSD11B1 1900/4885CYP2C9 439/4885EPHX2 3379/4885 |
| US-20210228565-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | HSD11B1 4136/4885CYP2C9 4859/4885EPHX2 3912/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | HSD11B1 43/4885CYP2C9 196/4885EPHX2 1296/4885 |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | HSD11B1 4136/4885CYP2C9 4859/4885EPHX2 3912/4885 |
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | PNKP, POLL, RNGTT | HSD11B1 3436/4885CYP2C9 1768/4885EPHX2 271/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | HSD11B1 4136/4885CYP2C9 4859/4885EPHX2 3912/4885 |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | PNKP, POLL, RNGTT | HSD11B1 3450/4885CYP2C9 1804/4885EPHX2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.